Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 10/20 | 0.61 |
| ▸ | PNP | P00491 | 10/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11730994 | 0.97 | HPRT1 (0.60) | HPRT1PNPUSP2TSHREDNRA | |
| Phosphoric Acid SCHEMBL6439956 | 0.95 | HPRT1 (0.65) | HPRT1PNPUSP2TSHREDNRA | |
| Phosphoric Acid SCHEMBL11308939 | 0.95 | HPRT1 (0.65) | HPRT1PNPUSP2TSHREDNRA | |
| Phosphoric Acid SCHEMBL11313332 | 0.94 | HPRT1 (0.64) | HPRT1PNPUSP2TSHREDNRA | |
| Phosphoric Acid SCHEMBL11327667 | 0.94 | HPRT1 (0.64) | HPRT1PNPUSP2TSHREDNRA | |
| Phosphoric Acid SCHEMBL11310331 | 0.94 | HPRT1 (0.64) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL8842510 | 0.93 | HPRT1 (0.58) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL9057761 | 0.91 | HPRT1 (0.59) | HPRT1PNPUSP2TSHREDNRA | |
| Water SCHEMBL11469150 | 0.90 | HPRT1 (0.56) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL8149575 | 0.90 | HPRT1 (0.60) | HPRT1PNPUSP2TSHREDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116804661-A | Method for measuring formaldehyde content in antiviral drug of lovir raw material drug by HPLC | 湖北省宏源药业科技股份有限公司 | 2023-09-26 | — | — | CN | claimed |
| EP-2851368-B1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU WDS FARMA (RU) | 2019-01-02 | — | — | EP | claimed |
| US-9745337-B2 | Complex compounds of germanium, methods for producing same, and drugs | OBSCHESNO S OGRANICHENNOI OTVETSTVENNOSTYU “WDS FARMA” (RU) | 2017-08-29 | — | — | US | claimed |
| US-20170112792-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2017-04-27 | — | — | US | claimed |
| WO-2015143190-A1 | ENHANCED ATRA-RELATED COMPOUNDS DERIVED FROM STRUCTURE-ACTIVITY RELATIONSHIPS AND MODELING FOR INHIBITING PIN1 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2015-09-24 | — | — | WO | claimed |
| US-20150126726-A1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTYU "WDS FARMA" (RU) | 2015-05-07 | — | — | US | claimed |
| EP-2851368-A1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | Obschestvo S Ogranichennoi Otvetstvennostyu "WDS FARMA" (RU) | 2015-03-25 | — | — | EP | claimed |
| CN-100531736-C | Application of 9 - (2 - hydroxyethoxy methyl)guanine in preparing silkworm drug | YUANDUO ZHOU (CN) | 2009-08-26 | — | — | CN | claimed |
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| CN-101091712-A | Application of 9 - (2 - hydroxyethoxy methyl) in preparing silkworm drug | YUANDUO ZHOU (CN) | 2007-12-26 | — | — | CN | claimed |
| US-4701526-A | Process for preparing 9-(2-hydroxyethoxymethyl)-guanine, and intermediates useful in said process | KRKA, TOVARNA ZDRAVIL, N.SOL.O. (YU) | 1987-10-20 | — | — | US | claimed |
| EP-0235931-A1 | Antiviral combination | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-09-09 | — | — | EP | claimed |
| EP-0220657-A2 | Conjugate of 9-(2-hydroxyethoxymethyl)-guanine with lactosaminated human albumin, process for the peparation thereof and pharmaceutical compositions containing it | LABORATORI BALDACCI Spa (IT) | 1987-05-06 | — | — | EP | claimed |
| EP-0217580-A2 | Therapeutic nucleosides | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-04-08 | — | — | EP | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| EP-0143987-A1 | Therapeutic compositions endowed with antiviral activity | Stendardi, Anna Gioia (IT) | 1985-06-12 | — | — | EP | claimed |
| EP-0135713-A2 | Antiviral combinations | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-04-03 | — | — | EP | claimed |
| EP-0044543-B1 | TOPICAL FORMULATIONS OF 9-(2-HYDROXYETHOXYMETHYL) GUANINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-06-06 | — | — | EP | claimed |
| EP-0095813-A2 | Penetrating topical pharmaceutical compositions containing 9-(2-hydroxyethoxymethyl) guanine | THE PROCTER & GAMBLE COMPANY (US) | 1983-12-07 | — | — | EP | claimed |
| US-4199574-A | Methods and compositions for treating viral infections and guanine acyclic nucleosides | BURROUGHS WELLCOME CO. (US) | 1980-04-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126726-A1 | COMPLEX COMPOUNDS OF GERMANIUM, METHODS FOR PRODUCING SAME, AND DRUGS | GDA, ATIC, AGXT | HPRT1 96/4885PNP 65/4885USP2 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.